Odyssey Group International (ODYY) 10-K 31 Oct 22 2022 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jul. 31, 2022	Oct. 31, 2022	Jan. 31, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2022
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--07-31
Entity File Number	333-200785
Entity Registrant Name	ODYSSEY HEALTH, INC.
Entity Central Index Key	0001626644
Entity Tax Identification Number	47-1022125
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	2300 West Sahara Avenue
Entity Address, Address Line Two	Suite 800
Entity Address, Address Line Three	#4012
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89102
City Area Code	(702)
Local Phone Number	780-6559
Title of 12(b) Security	Common Stock ($0.001 par value)
Trading Symbol	ODYY
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 31,821,019
Entity Common Stock, Shares Outstanding		71,994,154
Auditor Firm ID	76
Auditor Name	Turner, Stone & Company, L.L.P.
Auditor Location	Dallas, Texas

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Current assets:
Cash	$ 72,534	$ 556,584
Prepaid expenses and other current assets	453,883	53,535
Total current assets	526,417	610,119
Property and equipment, net	0	414
Intangible assets, net	43,260	0
Total assets	569,677	610,533
Current liabilities:
Accounts payable	1,549,568	1,224,783
Accrued wages	896,700	259,487
Accrued Interest	110,063	32,351
Asset purchase liability	1,125,026	1,125,026
Note payable, directors and officers	125,000	0
Notes payable, net of unamortized beneficial conversion feature, debt discount and closing costs of $48,063 and $351,030	1,406,937	736,240
Total current liabilities	5,213,294	3,377,887
Commitments and contingencies (Note 5)
Stockholders' deficit:
Preferred stock, $.001 par value; 100,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $.001 par value; 500,000,000 shares authorized with 77,860,563 and 87,191,168 issued and outstanding	77,861	87,191
Additional paid-in capital	49,456,476	42,879,278
Accumulated deficit	(54,177,954)	(45,733,823)
Total stockholders’ deficit	(4,643,617)	(2,767,354)
Total liabilities and stockholders’ deficit	$ 569,677	$ 610,533

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Statement of Financial Position [Abstract]
Unamortized debt discount	$ 48,063	$ 351,030
Preferred Stock, Par Value	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	100,000,000	100,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000
Common Stock, Shares Issued	77,860,563	87,191,168
Common Stock, Shares Outstanding	77,860,563	87,191,168

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Income Statement [Abstract]
General and administrative expense	$ 6,789,556	$ 4,788,119
Research and development	1,317,024	1,632,593
In-process research and development	0	9,440,000
Loss from operations	(8,106,580)	(15,860,712)
Interest expense	(836,294)	(1,072,383)
Other income, net	498,743	50,000
Net loss and comprehensive loss	$ (8,444,131)	$ (16,883,095)
Basic net loss per share	$ (0.09)	$ (0.18)
Diluted net loss per share	$ (0.09)	$ (0.18)
Shares used for basic net loss per share	88,995,280	93,734,074
Shares used for diluted net loss per share	88,995,280	93,734,074

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Jul. 31, 2020	$ 88,560	$ 28,110,689	$ (28,850,728)	$ (651,478)
Beginning balance, shares at Jul. 31, 2020	88,559,978
Common stock issued for compensation and services	$ 5,965	240,285		246,250
Common stock issued for compensation and services, shares	5,965,000
Conversion of convertible notes debt financing	$ 1,233	542,617		543,850
Conversion of convertible notes debt financing, shares	1,233,228
Stock-based compensation		1,759,963		1,759,963
Common stock issued in connection with debt financing	$ 820	321,545		322,365
Common stock issued in connection with debt financing, shares	820,000
Common stock issued in equity financing	$ 4,933	2,976,042		2,980,975
Common stock issued in equity financing, shares	4,932,962
Warrants and beneficial conversion feature issued with debt and equity		653,836		653,836
Common stock issued in asset purchase agreement	$ 6,000	8,254,000		8,260,000
Common stock issued in asset purchase agreement, shares	6,000,000
Return of shares to treasury	$ (20,320)	20,300		(20)
Return of shares to treasury, shares	(20,320,000)
Net loss			(16,883,095)	(16,883,095)
Ending balance, value at Jul. 31, 2021	$ 87,191	42,879,278	(45,733,823)	(2,767,354)
Ending balance, shares at Jul. 31, 2021	87,191,168
Beginning balance, value at Jul. 31, 2020	$ 88,560	28,110,689	(28,850,728)	(651,478)
Beginning balance, shares at Jul. 31, 2020	88,559,978
Ending balance, value at Jul. 31, 2022	$ 77,861	49,456,476	(54,177,954)	(4,643,617)
Ending balance, shares at Jul. 31, 2022	77,860,563
Beginning balance, value at Jul. 31, 2021	$ 87,191	42,879,278	(45,733,823)	(2,767,354)
Beginning balance, shares at Jul. 31, 2021	87,191,168
Common stock issued for compensation and services	$ 4,245	1,777,405		1,781,650
Common stock issued for compensation and services, shares	4,245,000
Common stock issued in connection with Prevacus milestone	$ 1,000	(1,000)
Common stock issued in connection with Prevacus milestone, shares	1,000,000
Stock-based compensation		2,088,815		2,088,815
Common stock issued in connection with debt financing	$ 300	68,418		68,718
Common stock issued in connection with debt financing, shares	300,000
Common stock issued in equity financing	$ 8,655	2,460,567		2,469,222
Common stock issued in equity financing, shares	8,653,973
Beneficial conversion feature issued with debt		159,463		159,463
Return of shares to treasury	$ (23,530)	23,530
Return of shares to treasury, shares	(23,529,578)
Net loss			(8,444,131)	(8,444,131)
Ending balance, value at Jul. 31, 2022	$ 77,861	$ 49,456,476	$ (54,177,954)	$ (4,643,617)
Ending balance, shares at Jul. 31, 2022	77,860,563

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Cash flows from operating activities
Net loss	$ (8,444,131)	$ (16,883,095)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,374	5,552
Stock issued for services and stock-based compensation	3,870,465	2,006,193
Amortization of beneficial conversion feature, debt discount and closing costs	687,429	858,942
Stock issued for in-process research and development	0	8,260,000
Financing costs paid with stock	68,718	169,000
Gain on forgiveness of long-term debt	0	(50,000)
Changes in operating assets and liabilities:
(Increase)/decrease in prepaid expenses	(400,348)	(16,869)
Increase in accounts payable	324,785	1,000,396
Increase (decrease) in accrued wages	637,213	47,785
Increase in accrued interest	77,712	53,959
Increase in asset purchase liability	0	1,125,026
Net cash used in operating activities	(3,175,783)	(3,423,111)
Cash flows from investing activities
Intellectual Property	(45,220)	0
Cash flows from financing activities
Proceeds from notes payable	375,000	1,565,000
Financing closing costs paid with cash	0	(169,000)
Principal payments made on notes payable	(107,269)	(415,232)
Proceeds from equity financing	2,469,222	2,935,975
Net cash provided by financing activities	2,736,953	3,916,743
Net change in cash	(484,050)	493,632
Cash, beginning of year	556,584	62,952
Cash, end of year	72,534	556,584
Supplemental disclosure of cash flow information
Cash paid for interest	954	34,345
Common stock issued for conversion of notes payable and related accrued interest	0	543,850
Common stock issued for debt financing commitment shares	68,718	322,365
Warrants issued in connection with financings	0	634,056
Original issue discount on debt	0	100,000
Beneficial conversion feature recognized	200,100	19,780
Accounts payable converted into common stock	20,000	45,000
Increase in principal of notes payable	225,000	0
Common stock issued for Prevacus milestone	1,000	0
Shares returned to treasury	$ 23,530	$ 20,300

Nature of Operations and Going

Nature of Operations and Going Concern	12 Months Ended
	Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations and Going Concern	Note 1. Nature of Operations and Going Concern Our corporate mission is to create or acquire distinct assets, intellectual property, and technologies with an emphasis on acquisition targets that have clinical utility and will generate positive cash flow. Our business model is to develop or acquire medical related products, engage third parties to manufacture such products and then distribute the products through various distribution channels, including third parties. We have three different life saving technologies; the CardioMap® heart monitoring and screening device, the Save a Life choking rescue device and a unique neurosteroid drug compound intended to treat concussions and rare brain disorders. We intend to acquire other technologies and assets and plan to be a trans-disciplinary product development company involved in the discovery, development and commercialization of products and technologies that may be applied over various medical markets. We plan to license, improve and/or develop our products and identify and select distribution channels. We intend to establish agreements with distributors to get products to market quickly as well as to undertake and engage in our own direct marketing efforts. We will determine the most effective method of distribution for each unique product that we include in our portfolio. We will engage third-party research and development firms who specialize in the creation of our products to assist us in the development of our own products and we will apply for trademarks and patents once we have developed proprietary products. We are not currently selling or marketing any products, as our products are in development and Food and Drug Administration ("FDA") clearance or approval to market our products will be required to sell in the United States. In addition, it would require additional European union or country specific clearance or approvals to sell internationally. We did not recognize any revenues for the years ended July 31, 2022 (“fiscal 2022”) or 2021 (“fiscal 2021”) and we had an accumulated deficit of $ 54,177,954 72,534 We follow the provisions of Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”), Topic 205-40, “Presentation of Financial Statements — Going Concern”, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the consolidated financial statements are issued. Based on our available cash as of July 31, 2022, management has concluded that substantial doubt exists about our ability to continue as a going concern for one year from the date these financial statements are issued. We expect to seek additional funding to sustain its future operations and while we have successfully raised capital in the past, the ability to raise capital in future periods is not assured. The consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The operating deficit raises substantial doubt about our ability to continue as a going concern. Our continued existence depends on the success of our efforts to raise additional capital necessary to meet our obligations as they come due and to obtain sufficient capital to execute our business plan. We may obtain capital primarily through issuances of debt or equity or entering into collaborative arrangements with corporate partners. There can be no assurance that we will be successful in completing additional financing or collaboration transactions or, if financing is available, that it can be obtained on commercially reasonable terms. If we are not able to obtain the additional financing on a timely basis, we may be required to further scale down or perhaps even cease operations. The issuance of additional equity securities could result in a significant dilution in the equity interests of our current stockholders. Obtaining commercial loans, assuming those loans would be available, would increase our liabilities and future cash commitments. Our financial statements do not include adjustments that might result from the outcome of this uncertainty. As COVID-19 pandemic continues to severely impact the U.S. and global economy, our business may be impacted in a variety of ways. Political, legal or regulatory actions as a result of the COVID-19 pandemic in jurisdictions where we may plan to manufacture, source or distribute products have created supply disruptions which could affect our plans, and may cause additional supply disruptions or shortages in the future. We cannot currently predict the frequency, duration or scope of these governmental actions and supply disruptions. If we are unable to raise additional capital by October 28, 2023, we will adjust our current business plan. Due to the unknown and volatile nature of the stock price and trading volume of our common stock, is it is difficult to predict the timing and amount of availability pursuant to our equity line of credit with LPC (Note 8). Given our recurring losses, negative cash flow, accumulated deficit, and the impact of COVID-19, there is substantial doubt about our ability to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jul. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Consolidation The consolidated financial statements include the accounts of Odyssey Health, Inc. and our wholly-owned subsidiary Odyssey Group International Australia, Pty Ltd. All intercompany balances and transactions have been eliminated. Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Basis of accounting We measure all of our assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP. Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the Australian research and development and GST tax rebates, loans and advances receivable and prepaid insurance. At July 31, 2022 there were no impairment concerns. Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. We recognized depreciation expense of $ 414 552 Intangible assets, net Intangible assets consist of costs related to a patent for our PRV-002 drug device combination are analyzed for potential impairment at least annually or whenever events or changes in circumstances indicate the carrying value may not be recoverable and exceeds the fair value, which is the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the intangible assets. We recognized amortization expense of $ 1,960 5,000 Future amortization of intangible assets is as follows: Schedule of future amortization expense assets Fiscal 2023 $ 3,015 Fiscal 2024 3,015 Fiscal 2025 3,015 Fiscal 2026 3,015 Fiscal 2027 3,015 Thereafter 28,185 Total $ 43,260 Beneficial conversion feature of convertible notes payable The Beneficial Conversion Feature (“BCF”) of a convertible note (Note 6) is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. We record a BCF related to the issuance of a convertible note when issued. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed giving effect to all potentially dilutive common stock and common stock equivalents, including stock options, convertible notes, RSUs and warrants. Basic and diluted net loss per share were the same for all periods presented as we were in a loss position for all periods. The following securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive: Schedule of antidilutive shares Fiscal Year Ended July 31, 2022 2021 Options to purchase common stock 6,645,000 300,000 Equivalent shares of convertible notes into common stock 7,303,333 1,134,000 Warrants to purchase common stock 7,558,607 4,739,834 Unvested restricted stock units 2,189,695 2,678,181 Total potentially dilutive securities 23,696,635 8,852,015 Stock-based compensation We recognize compensation expense for all restricted stock and stock option awards made to employees, directors and independent contractors. The fair value of stock option awards (Note 7) is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes pricing model is affected by our stock price, as well as by assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk free interest rate, expected dividends and projected stock option exercise behaviors. We estimate volatility based on historical volatility of our common stock, and estimate the expected term based on several criteria, including the vesting period of the grant and the term of the award. We estimate stock option exercise behavior based on assumptions regarding future exercise activity of unexercised, outstanding options. The fair value of stock awards is determined based on the fair value of our common stock on the date of grant. Fair value measurements The carrying values of cash, prepaid expenses and other current assets, accounts payable and accrued wages approximate their estimated fair values because of the short-term nature of these instruments. Research and development expense Research and development costs are expensed in the period when incurred. In-process research and development In-process research and development relates to acquired research and development for a product that is not yet being sold and is expensed upon purchase. We recognized in-process research and development expense of $ 9,440,000 Income taxes Income taxes are accounted for based upon an asset and liability approach. Accordingly, deferred tax assets and liabilities arise from the difference between the tax basis of an asset or liability and its reported amount in the financial statements. Deferred tax amounts are determined using the tax rates expected to be in effect when the taxes will actually be paid or refunds received, as provided under currently enacted tax law. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable, respectively, for the period plus or minus the change in deferred tax assets and liabilities during the period. Accounting guidance requires the recognition of a financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant tax authority. We believe our income tax filing positions and deductions will be sustained upon examination and, accordingly, no reserves or related accruals for interest and penalties have been recorded at July 31, 2022 or 2021. We recognize interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense.

New Accounting Pronouncements

New Accounting Pronouncements	12 Months Ended
	Jul. 31, 2022
Accounting Changes and Error Corrections [Abstract]
New Accounting Pronouncements	Note 3. New Accounting Pronouncements ASU 2019-12 In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, “Income Taxes (Topic 740),” which simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption of the amendments is permitted, including adoption in any interim period for which financial statements have not yet been issued. The adoption of ASU 2019-12 effective August 1, 2021, on a prospective basis did not have a material effect on our financial position, results of operations, or cash flows. ASU 2020-06 In August 2020, the FASB issued ASU 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40),” which simplifies the accounting for convertible instruments, reduces complexity for preparers and practitioners and improves the decision usefulness and relevance of the information provided to financial statement users. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. We have not yet determined the impact of adopting this standard on our financial position, results of operations or cash flows.

Asset Purchase Agreement and As

Asset Purchase Agreement and Asset Purchase Liability	12 Months Ended
	Jul. 31, 2022
Asset Purchase Agreement And Asset Purchase Liability
Asset Purchase Agreement and Asset Purchase Liability	Note 4. Asset Purchase Agreement and Asset Purchase Liability On January 7, 2021, we entered into an Asset Purchase Agreement (the “APA”) with Prevacus, Inc. (“Prevacus”), pursuant to which we purchased the assets and all of the rights, interests and intellectual property in a certain drug program (PRV-002) for treating mild brain trauma (concussion) and the delivery device (collectively, the “Asset”) in exchange for (i) 7,000,000 The Milestone Consideration (“Milestone”) may be earned by Prevacus as follows: (i) 2,000,000 shares of our Common Stock when the United States Patents are revived in our name by the U.S. Patent and Trademark Office and any international patents that have lapsed also revived in our name by the respective country’s patent offices. The value of shares issued were not to exceed $6.0 million based on the price of our common stock on the date the payment would have been due. This milestone will not be met as the relevant patents lapsed; (ii) 1,000,000 shares of our common stock upon successful first dosing in a Phase I Clinical Trial for the Asset. This milestone was met in March 2022; (iii) 2,000,000 shares of our common stock upon the grant and issuance to us of a Patent for the Asset from the U.S. Patent and Trademark Office, the value of which shall not exceed $10.0 million based on the price of our common stock on the date the payment is due; (iv) 1,000,000 shares of our common stock upon our receipt of net proceeds of at least $1.0 million in a Non-Dilutive Financing relating directly to the development of the Asset within one year after the Closing Date or, in the event of any Non-Dilutive Financing submitted prior to the one-year anniversary of the Closing Date, the milestone will stay effective until the second year anniversary of the Closing Date. This milestone will not be met as the one-year deadline lapsed; (v) 2,000,000 shares of our common stock if we sell the Asset to a Third Party resulting in net proceeds to us of at least $50.0 million after a Phase IB Clinical Trial for which we are the sponsor is complete, but prior to completion of a Phase II Clinical Trial. The value of the 2,000,000 shares related to this milestone shall not exceed $25.0 million based on the price of our common stock on the date the payment is due; (vi) 4,000,000 shares of our common stock upon the successful completion of a Phase II Clinical Trial for the Asset that leads to (I) our sale of the Asset to a Third Party resulting in net proceeds to us of at least $50.0 million; or (II) the administration of the first dose in a Phase III Clinical Trial for the Asset for which we are, or one of our affiliates or licensees is the sponsor; and (vii) 2,000,000 shares of our common stock after the first dosing in a Phase II Clinical Trial and the successful completion of a Phase 1B human clinical trial. All Milestone payments shall only be paid once, upon the initial achievement of the particular Milestone event. We, at our sole and absolute discretion, shall determine if any Milestone event has occurred. To extent the related milestones are not achieved, the above-mentioned Milestone payments will terminate and cease to exist, and we will no longer be liable thereunder, if said Milestone is not completed within four years after the Closing Date. See Note 5 for additional information. On March 1, 2021 (the “Closing Date”), our APA with Prevacus closed and we issued 6,000,000 shares of our common stock valued at $1.18 per share for the stock granted on the date of acquisition for $ 7,080,000 1,000,000 1,180,000 In addition, 1,000,000 1,180,000 We determined that, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 730 Research and Development (ASC 730-10-25-2(c)) and pursuant to ASC 730-10-25-2(c), intangibles purchased from others for use in particular research and development projects and that have no alternative future use in research and development or otherwise, represent costs of research and development as acquired, and therefore are expensed when incurred. Accordingly, On March 1, 2021, the date of acquisition, we expensed $ 9,440,000

Fair Value

Fair Value	12 Months Ended
	Jul. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value	Note 5. Fair Value The fair value of financial assets and liabilities are determined utilizing a three-level framework as follows: Level 1 – Observable inputs, such as unadjusted quoted prices in active markets, for substantially identical assets and liabilities. Level 2 – Observable inputs other than quoted prices within Level 1 for similar assets and liabilities. These include quoted prices for similar assets and liabilities in active markets, quoted prices for identical assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. If the asset or liability has a specified or contractual term, the input must be observable for substantially the full term of the asset or liability. Level 3 – Unobservable inputs that are supported by little or no market activity, generally requiring a significant amount of judgment by management. The methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Further, although we believe our valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date. We did not have any transfers of assets or liabilities measured at fair value on a recurring basis to or from Level 1, Level 2 or Level 3 during the fiscal years ended July 31, 2022 or 2021. No changes were made to our valuation techniques during the fiscal year ended July 31, 2022. Contingent Liabilities At July 31, 2022 and 2021, we had contingent consideration related to the acquisition of intellectual property, know-how and patents for an anti-choking, life-saving medical device in fiscal 2019. According to the agreement, we will make a one-time cash payment totaling $250,000 upon FDA clearance of the device. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). We determined the value was zero at both periods since it is not yet probable that we will file for FDA clearance. We also had contingent consideration at July 31, 2022 and 2021 related to milestones in our Asset Purchase Agreement with Prevacus, Inc. The fair value of the contingent consideration is reviewed quarterly and determined based on the current status of the project (Level 3). Based on these reviews, the fair value of the contingent consideration was determined to be zero at both periods as it is not yet probable that any of the milestones will be met. Fixed-Rate Debt We have fixed-rate debt that is reported on our Balance Sheets at carrying value less unamortized debt discount and closing costs. The fair value of our fixed rate debt was calculated using a discounted cash flow methodology with estimated current interest rates based on similar risk profile and duration (Level 2). The carrying value, excluding unamortized debt discount and debt issuance costs, and the fair value of our fixed-rate long-term debt was as follows: Schedule of fixed-rate debt July 31, 2022 2021 Carrying value $ 1,580,000 $ 1,087,270 Fair value $ 1,580,000 $ 1,094,212 Non-Financial Assets Non-financial assets, such as Property and equipment and Intangible assets, are measured at fair value on a non-recurring basis when events or circumstances indicate that an impairment may have occurred. If we determine these assets to be impaired, they are reported at fair value as calculated during the period. No non-financial assets were recorded at fair value during fiscal 2022 or 2021.

Debt

Debt	12 Months Ended
	Jul. 31, 2022
Debt Disclosure [Abstract]
Debt	Note 6. Debt Promissory Notes On December 21, 2021, and December 22, 2021, we entered into a total of five Promissory Notes (the “Notes”) with three of our directors and two officers. Mr. Joseph Michael Redmond, President and Chief Executive Officer, Ms. Christine M. Farrell, Chief Financial Officer, Mr. Jerome H. Casey, Director, Mr. John P. Gandolfo, Director, and Mr. Ricky W. Richardson, Director, each loaned us $ 25,000 125,000 8 December 31, 2022 6,063 Tysadco Partners On August 29, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Tysadco Partners (“Tysadco”) pursuant to which we entered into a $ 250,000 8.0 March 1, 2022 250,000 200,000 17,718 0.30 983,333 On March 31, 2022, the SPA was amended to extend the maturity date to March 1, 2023 25,000 LGH Investments, LLC April 2021 Promissory Note On April 5, 2021, we entered into a Securities Purchase Agreement with LGH Investments, LLC (“LGH”) pursuant to which we entered into a $ 1,050,000 8.0 On February 15, 2022, we entered into Amendment No. 1 (the “Amendment”) to the Note with an effective date of February 1, 2022 February 5, 2022 May 31, 2022 200,000 100,000 51,000 250,000 1.00 1,336,000 In June 2022, the maturity date of the LGH Note was extended to August 30, 2022 0.20 200,100 125,989 At July, 31, 2022 we paid $ 70,000 1,180,000 0.20 6,320,000 The 2021 LGH Agreement included the issuance of a five-year share purchase warrant exercisable for 1,134,000 shares of our common stock at a price of $0.95 per share and 100,000 shares of our common stock. The value of the 1,134,000 877,716 423,003 100,000 85,000 40,965 463,968 Labrys Fund, LP On August 14, 2020, we entered into a Securities Purchase Agreement (the “Labrys SPA”) with Labrys Fund, LP (“Labrys”), pursuant to which Labrys purchased a $ 350,000 315,000 420,000 197,400 We paid Alliance Global Partners, LLP (“A.G.P.”) as a placement agent a fee of $ 25,200 6,500 31,700 Conversion of Convertible Notes Payable On August 14, 2020, we converted a convertible promissory note with a face value of $ 100,000 7,000 214,000 In February 2021, we settled a convertible promissory note with a face value of $ 20,000 1,400 In February, March and April 2021, upon maturity, we converted five convertible promissory notes with an aggregate face value of $ 230,000 16,100 298,165 In May 2021, upon maturity, we converted four convertible promissory notes with an aggregate face value of $ 95,000 6,650 127,063 PPP Loan On February 11, 2021, we received notice that the SBA Paycheck Protection Program loan for $50,000 was forgiven. The $ 50,000 Notes Payable Outstanding Schedule of Notes Payable July 31, 2022 July 31, 2021 Note issued to Labrys due August 14, 2021 with an interest rate of 12% $ – $ 37,270 Convertible note issued to LGH due August 30, 2022 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 5.22%) and convertible at $0.20 per share 1,180,000 1,050,000 Promissory notes issued to officers and directors due December 31, 2022 with a fixed interest rate of 8.0% per annum (see Note 6) 125,000 – Tysadco convertible promissory note payable due March 1, 2023 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 5.09%) and convertible at $0.30 per share 275,000 – 1,580,000 1,087,270 Unamortized debt discount, closing costs and beneficial conversion feature (48,063 ) (351,030 ) $ 1,531,937 $ 736,240

Stock-Based Awards

Stock-Based Awards	12 Months Ended
	Jul. 31, 2022
Equity [Abstract]
Stock-Based Awards	Note 7. Stock-Based Awards 2021 Omnibus Stock Incentive Plan At our annual stockholder meeting held September 14, 2021, the stockholders approved the Amended and Restated 2021 Omnibus Stock Incentive Plan (the “2021 Plan”). The purpose of the 2021 Plan is to enable us to recruit and retain highly qualified employees, directors and consultants and to provide incentives for productivity and the opportunity to share in our growth and value. Subject to certain adjustments, the maximum number of shares of common stock, incentive stock options, stock appreciation rights, restricted stock, restricted stock units, cash or other stock-based awards that may be issued under the 2021 Plan is 20,000,000. At July 31, 2022, 13,355,000 20,000,000 Grants to Directors, Officers and Named Executive Officers At our annual meeting held on September 14, 2021, the stockholders approved the Amended and Restated 2021 Omnibus Stock Incentive Plan, which grants Board members who have been elected to receive 500,000 RSUs immediately following the Annual Meeting (other than Mr. Richardson who received an initial equity grant upon joining the Board in May 2021), that vest monthly over 12 months from the date of grant. Messrs.. Casey, Conroy and Gandolfo received 500,000 On May 19, 2022, the Board granted 500,000 750,000 600,000 155,033 Stock Options Stock option activity during fiscal 2022 was as follows: Schedule of stock option activity Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2021 1,050,000 $ 1.22 Options granted 5,595,000 0.32 Options outstanding at July 31, 2022 6,645,000 0.46 Criteria used for determining the Black-Scholes value of options granted were as follows: Schedule of assumptions Year Ended July 31, 2022 2021 Expected stock price volatility 137 149 155 Risk free interest rate 1.17 3.02 0.08 Expected life of options (years) 3.0 10.0 3.0 Expected dividend yield – – Restricted Stock Units (“RSUs”) RSU activity during fiscal 2022 was as follows: Schedule of RSU activity Number of RSUs Weighted Average Grant Date Fair Value RSUs outstanding at July 31, 2021 4,396,819 $ 1.09 RSUs issued 1,500,000 0.45 RSUs vested (3,707,124 ) 0.37 RSUs outstanding at July 31, 2022 2,189,695 0.23 Warrants Warrant activity during fiscal 2022 was as follows: Schedule of warrant activity Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2021 4,739,834 $ 1.05 Warrants issued 4,304,607 0.57 Warrants canceled (1,485,834 ) (1.50 ) Warrants outstanding at July 31, 2022 7,558,607 0.69 Unrecognized Stock-Based Compensation Costs At July 31, 2022, we had total unrecognized stock-based compensation of $ 1,790,049 1.43

Common Stock

Common Stock	12 Months Ended
	Jul. 31, 2022
Equity [Abstract]
Common Stock	Note 8. Common Stock Treasury Shares In June 2021, Green Energy Alternatives, Inc. returned 5,300,000 In July 2021, Electromedica, LLC returned 15,000,000 On August 5, 2021, our loan with Labrys Fund, LP was repaid in full and, per the agreement, on August 6, 2021, 350,000 restricted stock shares were returned to treasury. On December 21, 2021, Vivakor, Inc., a shareholder, returned 3,309,578 On December 29, 2021, Regal Growth, LLC, a shareholder, returned 5,000,000 On February 2, 2022, LBL Professional Consulting, Inc., a shareholder, returned 7,500,000 On July 27, 2022, PLC Investments, Inc., a shareholder, returned 7,370,000 Common Stock Issued for Services In January 2021, we entered into three agreements for consulting services to be provided. We granted the consultants 540,000 88,000 On February 12, 2021, we entered into an agreement for consulting services to be provided through February 2022. We granted the consultant 75,000 93,750 On March 1, 2021, we entered into an agreement for consulting services to be provided through February 2022. We granted the consultant 25,000 29,500 On February 9, 2022, in connection with an investor relations consulting agreement with Tysadco, we issued Tysadco 3,000,000 0.53 On May 8, 2022, we entered into a six month consulting agreement for investor relations services. We granted the investor relations firm 45,000 16,650 On May 19, 2022, we entered into a six month consulting agreement for investor relations services. We granted the investor relations firm 500,000 115,000 On June 10, 2022, in connection with our agreement with Prevacus entered into on March 1, 2021, we issued Prevacus 1,000,000 On July 20, 2022, we entered into a consulting agreement for investor relations services. We granted the investor relations firm 200,000 40,000 Common Stock Issued for Compensation On July 31, 2021, Mr. Redmond received 5.3 53,000 5.3 Reverse Split At our 2021 annual stockholder meeting, which was held on September 14, 2021, the stockholders approved the proposal that granted the Board discretionary authority to amend our Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of our common stock. As determined by our Board, such stock split could be effected at a time and choosing of the Board. The amendment did not change the number of authorized shares of common stock or preferred stock or the relative voting power of our stockholders. The number of authorized shares will not be reduced. The number of authorized but unissued shares of our common stock will materially increase and will be available for re-issuance. We reserve the right not to effect any reverse stock split if the Board does not deem it to be in the best interests of our stockholders and the Board’s decision as to whether and when to effect the reverse stock split will be based on a number of factors, including prevailing market conditions, existing and expected trading prices for our common stock, actual or forecasted results of operations, and the likely effect of such results on the market price of our common stock. Tysadco Partners On October 18, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Tysadco Partners (“Tysadco”) pursuant to which we received $ 250,000 1,500,000 833,333 0.50 5 In June 2021, we sold 500,000 0.59 500,000 1.00 295,000 250,000 45,000 Lincoln Park Capital Fund October 2021 Securities Purchase Agreement On October 22, 2021, we entered into a Securities Purchase Agreement (the “SPA”) with Lincoln Park Capital Fund, LLC (“LPC”) pursuant to which we received $ 250,000 1,500,000 833,333 0.50 5 August 2020 Securities Purchase Agreement On August 14, 2020, we entered into a Purchase Agreement (the “LPC Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park” or “LPC”). Pursuant to the LPC Purchase Agreement, we have the right, in our sole discretion, to sell to LPC up to $10,250,000 in shares of our common stock, from time to time over a 36-month period. In consideration for entering into the LPC Purchase Agreement, we issued 793,802 Upon entering into the LPC Purchase Agreement, we sold 602,422 250,000 In addition, if we have directed LPC to purchase the full amount of common stock available as a Regular Purchase on a given day, we may direct LPC to purchase additional amounts as “accelerated purchases” and “additional accelerated purchases” as set forth in the LPC Purchase Agreement. The purchase price of shares of our common stock will be based on the then prevailing market prices of such shares at the time of sale. The LPC Purchase Agreement limits our sale of shares of common stock to LPC, and LPC’s purchase or acquisition of common stock from us, to an amount of common stock that, when aggregated with all other shares of our common stock then beneficially owned by LPC would result in LPC having beneficial ownership, at any single point in time, of more than 4.99% of the then total outstanding shares of our common stock. The LPC Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions. LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our common stock. The LPC Purchase Agreement does not limit our ability to raise capital from other sources in our sole discretion; provided, however, that we shall not enter into any “Variable Rate Transaction” as defined in the LPC Purchase Agreement, including the issuance of any floating conversion rate or variable priced equity-like securities, but excluding any “At-the-Market” offering with a registered broker-dealer, until the later of (i) the 36-month anniversary of the date of the LPC Purchase Agreement, and (ii) the 36-month anniversary of the Commencement Date (if the Commencement has occurred), in either case irrespective of any earlier termination of the LPC Purchase Agreement. The LPC Purchase Agreement may be terminated by us at any time and at our discretion without any cost to us. In connection with the LPC transaction, we engaged A.G.P. as a placement agent to help raise capital. A.G.P. introduced us to LPC, for which we agreed to pay A.G.P. a fee of 8% of the amount of the funds received from LPC, which totaled $ 20,000 97,718 13,750 In addition, and in consideration for the service provided in connection with Labrys and LPC, we granted warrants that were immediately exercisable for a total of 550,000 0.50 220,000 August 6, 2024 Shares purchased by LPC, including the initial purchase, are summarized below: Schedule of Shares purchased Purchase Date Number of Shares Average Purchase Price per Share Total Purchase Price Remaining Purchase August 14, 2020 602,422 $ 0.410 $ 250,000 $ 10,000,000 January 2021 200,000 0.175 35,080 9,964,920 February 2021 330,106 0.626 206,798 9,758,122 March 2021 1,020,798 0.960 979,597 8,778,525 August 2021 600,000 0.397 237,940 8,540,585 September 2021 374,482 0.345 129,096 8,411,489 February 2022 100,000 0.515 51,500 8,359,989 March 2022 100,000 0.487 48,700 8,311,289 July 2022 421,119 0.194 81,556 8,229,733 3,748,927 0.539 $ 2,020,267 See Note 13 for information regarding subsequent sales to LPC. LGH In connection with an amendment to the LGH Note, we issued LGH 100,000 51,000 Private Placement On February 2, 2022, we entered into an agreement to raise money through a private investment in a public entity (“PIPE”). We offered up to 14,285,714 0.35 0.70 5 The Offering was made on a “Minimum” basis, meaning a minimum amount of money must be raised. The minimum amount of $ 1,000,000 2,870,800 1,435,400 1,004,780 849,302 On May 3, 2022, the second closing of the PIPE occurred, pursuant to which we issued 1,187,572 1,187,572 0.25 593,786 415,650 374,085 608,755 0.35 In connection with the Offering, we paid Laidlaw & Company (UK) Ltd. (“Laidlaw”), our introducing broker, 10% of the proceeds, or $ 100,478 We filed a Form S-1 on July 29, 2022 to register all shares issued and issuable pursuant to the PIPE and it became effective on August 9, 2022.

Income Taxes

Income Taxes	12 Months Ended
	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes We file income tax returns in the U.S. federal jurisdiction and the various states in which we operate. We registered with the Franchise Tax Board in the State of California in tax year 2020. Our tax returns are not currently under examination for any year. Our deferred tax assets consist of federal net operating loss carryforwards that expire through the year 2036 The following table reconciles the U.S. federal statutory rate to our effective tax rate: Schedule of Effective Income Tax Rate Reconciliation For the year ended July 31, 2022 2021 US federal statutory rates 21% 21% Valuation allowance (21 )% (21)% Effective tax rate 0% 0% Our tax provision (benefit) was as follows: Schedule of Components of Income Tax Expense (Benefit) For the year ended July 31, 2022 2021 Current deferred $ 885,400 $ 1,182,300 Increase in valuation allowance (885,400 ) (1,182,300 ) Total $ – $ – Our net deferred tax asset was as follows: Schedule of Deferred Tax Assets and Liabilities For the year ended July 31, 2022 2021 Deferred tax asset $ 2,475,100 $ 1,589,700 Valuation allowance (2,475,100 ) (1,589,700 ) Net deferred tax asset $ – $ – As of July 31, 2022, we had $ 11,434,941 We provide for a valuation allowance when it is more likely than not that they will not realize a portion of the deferred tax assets. We established a valuation allowance against our net deferred tax asset due to the uncertainty that enough taxable income will be generated in those taxing jurisdictions to utilize the assets. Therefore, we have not reflected any benefit from such deferred tax assets in the accompanying financial statements. We reviewed the issuance of stock to certain senior executives who received stock in conjunction with becoming an officer and director. In this case, as an officer and director of a publicly-traded company, the sale of shares could be subject to the short-swing profits rules of Securities Exchange Act Section 16(b) and is subject to a substantial risk of forfeiture per IRC § 83 (c)(3)(A). Given that such stock is subject to a substantial risk of forfeiture, such stock is treated as nonvested stock under IRC § 83. As the stock received was nonvested stock, income inclusion is deferred until the year in which the stock vests unless the employee makes an affirmative election to include income in the year of receipt. We reviewed all income tax positions taken or that are expected to be taken for all open years and determined that our income tax positions are appropriately stated and supported for all open years. We are subject to U.S. federal income tax examinations by tax authorities for years after 2020 due to unexpired net operating loss carryforwards originating in and subsequent to that year. We may be subject to income tax examinations for the various taxing authorities which vary by jurisdiction. Our policy is to record interest and penalties associated with unrecognized tax benefits as additional income taxes in the statements of operations. As of July 31, 2022, there were no

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jul. 31, 2022
Related Party Transactions [Abstract]
Related Party Transactions	Note 10. Related Party Transactions Due to Officers The following amounts were due to our officers for reimbursement of expenses and were included in Accounts payable on our Balance Sheets: Schedule of related party payables July 31, 2022 2021 Joseph M. Redmond, CEO $ 2,642 $ 2,568 Christine Farrell, CFO 745 – $ 3,387 $ 2,568 The amount of unpaid salary and bonus due to our officers was included in Accrued wages on our Balance Sheets and was as follows: Schedule of accrued wages July 31, 2022 2021 Joseph M. Redmond, CEO $ 696,154 $ 183,846 Christine Farrell, CFO 124,617 – $ 820,771 $ 183,846 On January 31, 2022, the Compensation Committee and our full Board approved the 2021 bonus plan. Pursuant to the plan, Mr. Redmond received a $ 360,000 40,000 In December 2021, we entered into a total of five Promissory Notes with three of our directors and two officers. Mr. Joseph Michael Redmond, President and Chief Executive Officer, Ms. Christine M. Farrell, Chief Financial Officer, Mr. Jerome H. Casey, Director, Mr. John P. Gandolfo, Director, and Mr. Ricky W. Richardson, Director, each loaned us $25,000 for total proceeds of $125,000. At July 31, 2022, we recorded $6,063 of interest expense and accrued interest on these notes See also Note 6 for a discussion of $ 25,000 See also Note 7 for a discussion of RSUs and stock option grants to each of our four directors, two officers and Dr. VanLandingham. Related Party Transaction On November 7, 2017, Mr. Redmond entered into an employment agreement with us. As part of the employment agreement, Mr. Redmond was granted 25 million shares of common stock that vesting equally upon FDA submission of CardioMap, FDA approval for CardioMap and the raising of $2 million for further CardioMap development. Mr. Redmond could not sell the shares for two years or until we reached $10 million in revenues. Mr. Redmond was granted options for 15 million shares with an exercise price of $0.25 per share that vest equally upon our revenue reaching $5 million, $10, million and $15 million. The vesting accelerated based upon a change of control. None of these conditions were met and the options were canceled in September 2020. On February 16, 2018, the employment agreement was amended granting Mr. Redmond 10 million shares of common stock. No other provision of the employment contract was amended, and the amendment was explicit on that provision. On November 28, 2018, the employment agreement was again amended to include 4.7 million of the 10 million shares to be provided by us and 5.3 million to be provided by Green Energy Alternatives, LLC, which shares were returned to treasury in June 2021. No other provision of the employment contract was amended, and the amendment was explicit on that provision. On July 31, 2021, Mr. Redmond received 5.3 million shares of common stock to replace the unissued shares per his November 28, 2018 amended employment agreement. We recognized $53,000 of compensation expense related to the 5.3 million shares granted, with a fair value of $0.01 per share, during fiscal 2021. On March 1, 2021, as part of the Prevacus APA and Dr. VanLandingham’s employment agreement, Dr. VanLandingham was granted 1,000,000 941,000 250,000 shares vested on signing of closing documents; 250,000 shares vest on Phase 1A first dosing of human, 250,000 shares vest on Phase 1B first dosing of human; and 250,000 shares vest upon us being accepted on NASDAQ. 295,845 596,145 49,010 In March and May 2021, we entered in a letter agreement loan with Prevacus Inc. for $2,500 and $5,000, respectively. The loans have an annual interest rate of 3% per annum and principal and interest were due in June 2021. At July 31, 2022, the loans had not been repaid and continue to accrue interest. At July 31, 2022, we have advanced Dr. VanLandingham $ 27,500

Donation Received

Donation Received	12 Months Ended
	Jul. 31, 2022
Donation Received
Donation Received	Note 11. Donation Received On January 5, 2022, we received a donation in the amount of $ 500,000

Research and Development Rebate

Research and Development Rebate	12 Months Ended
	Jul. 31, 2022
Research and Development [Abstract]
Research and Development Rebate	Note 12. Research and Development Rebate In fiscal 2022, we received research and development and GST rebates from the government of Australia in the amount of $ 264,209 366,475

Subsequent Events

Subsequent Events	12 Months Ended
	Jul. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	Note 13. Subsequent Events On July 29, 2022 the Company filed Form S-1: General for Registration of Securities with the SEC, to register its shares from it PIPE for re-sale on the open market. The Form S-1 became effective August 9, 2022. In September and October 2022, two shareholders returned at total of 8,800,000 common stock shares to treasury and all rights, title and interest in the shares were relinquished. In September and October 2022, in connection with entering consulting agreements, we issued consultants 1,800,000 restricted shares of our common stock valued at an average price of $0.22 per share. On September 21, 2022, we entered into a promissory note for $30,000 with Jonathan Lutz, an accredited investor. The note bears an interest rate of 8% per annum and is due December 31, 2022. On September 29, 2022, we entered into Amendment No. 3 to the Convertible Promissory Note to the Securities Purchase Agreement dated April 5, 2021, with LGH Investments, LLC. Pursuant to the Amendment, the parties have agreed to extend the maturity date of the note to December 31, 2022. As consideration, $115,000 was added to the principal amount outstanding. All other terms and conditions remain the same. On September 30, 2022, we entered into five Promissory Note Amendments, to the Promissory Notes entered into December 21, 2021 and December 22, 2021 and as amended April 20, 2022, and June 3, 2022, with three directors and two officers. Pursuant to the Amendments, the parties have agreed to extend the maturity date of the Promissory Notes to December 31, 2022. All other terms and conditions remain the same. Subsequent to July 31, 2022 and through October 31, 2022, we sold an additional 1,133,591 shares of our common stock to LPC for total proceeds $240,710. Subsequent to July 31, 2022 and through October 31, 2022, we issued 3,250,000 stock options to consultants, employees and an officer at an average exercise price of $0.29 per share. The options have expirations dates of five and 10 years.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jul. 31, 2022
Accounting Policies [Abstract]
Basis of Consolidation	Basis of Consolidation The consolidated financial statements include the accounts of Odyssey Health, Inc. and our wholly-owned subsidiary Odyssey Group International Australia, Pty Ltd. All intercompany balances and transactions have been eliminated.
Use of estimates	Use of estimates The preparation of financial statements in conformity with Generally Accepted Accounting Principles (“GAAP”) generally requires management to make estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.
Basis of accounting	Basis of accounting We measure all of our assets and liabilities on the historical cost basis of accounting unless otherwise required by GAAP.
Prepaid expenses and other current assets	Prepaid expenses and other current assets Prepaid expenses and other current assets consist of the Australian research and development and GST tax rebates, loans and advances receivable and prepaid insurance. At July 31, 2022 there were no impairment concerns.
Property and equipment, net	Property and equipment, net Property and equipment is stated at cost less accumulated depreciation. Depreciation is recorded on a straight-line basis over the estimated useful lives of the assets. We recognized depreciation expense of $ 414 552
Intangible assets, net	Intangible assets, net Intangible assets consist of costs related to a patent for our PRV-002 drug device combination are analyzed for potential impairment at least annually or whenever events or changes in circumstances indicate the carrying value may not be recoverable and exceeds the fair value, which is the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the intangible assets. We recognized amortization expense of $ 1,960 5,000 Future amortization of intangible assets is as follows: Schedule of future amortization expense assets Fiscal 2023 $ 3,015 Fiscal 2024 3,015 Fiscal 2025 3,015 Fiscal 2026 3,015 Fiscal 2027 3,015 Thereafter 28,185 Total $ 43,260
Beneficial conversion feature of convertible notes payable	Beneficial conversion feature of convertible notes payable The Beneficial Conversion Feature (“BCF”) of a convertible note (Note 6) is normally characterized as the convertible portion or feature of certain notes payable that provide a rate of conversion that is below market value or in-the-money when issued. We record a BCF related to the issuance of a convertible note when issued. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded upon the occurrence of the event. The BCF of a convertible note is a reduction of the carrying amount of the convertible note equal to the intrinsic value of the conversion feature, both of which are credited to additional paid-in-capital and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Net loss per share	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share is computed giving effect to all potentially dilutive common stock and common stock equivalents, including stock options, convertible notes, RSUs and warrants. Basic and diluted net loss per share were the same for all periods presented as we were in a loss position for all periods. The following securities were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive: Schedule of antidilutive shares Fiscal Year Ended July 31, 2022 2021 Options to purchase common stock 6,645,000 300,000 Equivalent shares of convertible notes into common stock 7,303,333 1,134,000 Warrants to purchase common stock 7,558,607 4,739,834 Unvested restricted stock units 2,189,695 2,678,181 Total potentially dilutive securities 23,696,635 8,852,015
Stock-based compensation	Stock-based compensation We recognize compensation expense for all restricted stock and stock option awards made to employees, directors and independent contractors. The fair value of stock option awards (Note 7) is estimated at the grant date using the Black-Scholes option-pricing model, and the portion that is ultimately expected to vest is recognized as compensation cost over the requisite service period. We have elected to recognize compensation expense for all options with graded vesting on a straight-line basis over the vesting period of the entire option. The determination of fair value using the Black-Scholes pricing model is affected by our stock price, as well as by assumptions regarding a number of complex and subjective variables, including expected stock price volatility, risk free interest rate, expected dividends and projected stock option exercise behaviors. We estimate volatility based on historical volatility of our common stock, and estimate the expected term based on several criteria, including the vesting period of the grant and the term of the award. We estimate stock option exercise behavior based on assumptions regarding future exercise activity of unexercised, outstanding options. The fair value of stock awards is determined based on the fair value of our common stock on the date of grant.
Fair value measurements	Fair value measurements The carrying values of cash, prepaid expenses and other current assets, accounts payable and accrued wages approximate their estimated fair values because of the short-term nature of these instruments.
Research and development expense	Research and development expense Research and development costs are expensed in the period when incurred.
In-process research and development	In-process research and development In-process research and development relates to acquired research and development for a product that is not yet being sold and is expensed upon purchase. We recognized in-process research and development expense of $ 9,440,000
Income taxes	Income taxes Income taxes are accounted for based upon an asset and liability approach. Accordingly, deferred tax assets and liabilities arise from the difference between the tax basis of an asset or liability and its reported amount in the financial statements. Deferred tax amounts are determined using the tax rates expected to be in effect when the taxes will actually be paid or refunds received, as provided under currently enacted tax law. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. Income tax expense or benefit is the tax payable or refundable, respectively, for the period plus or minus the change in deferred tax assets and liabilities during the period. Accounting guidance requires the recognition of a financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement with the relevant tax authority. We believe our income tax filing positions and deductions will be sustained upon examination and, accordingly, no reserves or related accruals for interest and penalties have been recorded at July 31, 2022 or 2021. We recognize interest and penalties on unrecognized tax benefits as well as interest received from favorable tax settlements within income tax expense.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jul. 31, 2022
Accounting Policies [Abstract]
Schedule of future amortization expense assets	Schedule of future amortization expense assets Fiscal 2023 $ 3,015 Fiscal 2024 3,015 Fiscal 2025 3,015 Fiscal 2026 3,015 Fiscal 2027 3,015 Thereafter 28,185 Total $ 43,260
Schedule of antidilutive shares	Schedule of antidilutive shares Fiscal Year Ended July 31, 2022 2021 Options to purchase common stock 6,645,000 300,000 Equivalent shares of convertible notes into common stock 7,303,333 1,134,000 Warrants to purchase common stock 7,558,607 4,739,834 Unvested restricted stock units 2,189,695 2,678,181 Total potentially dilutive securities 23,696,635 8,852,015

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Jul. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of fixed-rate debt	Schedule of fixed-rate debt July 31, 2022 2021 Carrying value $ 1,580,000 $ 1,087,270 Fair value $ 1,580,000 $ 1,094,212

Debt (Tables)

Debt (Tables)	12 Months Ended
	Jul. 31, 2022
Debt Disclosure [Abstract]
Schedule of Notes Payable	Schedule of Notes Payable July 31, 2022 July 31, 2021 Note issued to Labrys due August 14, 2021 with an interest rate of 12% $ – $ 37,270 Convertible note issued to LGH due August 30, 2022 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 5.22%) and convertible at $0.20 per share 1,180,000 1,050,000 Promissory notes issued to officers and directors due December 31, 2022 with a fixed interest rate of 8.0% per annum (see Note 6) 125,000 – Tysadco convertible promissory note payable due March 1, 2023 with a fixed interest rate of 8.0% over the term of the note (annual interest rate of 5.09%) and convertible at $0.30 per share 275,000 – 1,580,000 1,087,270 Unamortized debt discount, closing costs and beneficial conversion feature (48,063 ) (351,030 ) $ 1,531,937 $ 736,240

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	12 Months Ended
	Jul. 31, 2022
Equity [Abstract]
Schedule of stock option activity	Schedule of stock option activity Number of Options Weighted Average Exercise Price Options outstanding at July 31, 2021 1,050,000 $ 1.22 Options granted 5,595,000 0.32 Options outstanding at July 31, 2022 6,645,000 0.46
Schedule of assumptions	Schedule of assumptions Year Ended July 31, 2022 2021 Expected stock price volatility 137 149 155 Risk free interest rate 1.17 3.02 0.08 Expected life of options (years) 3.0 10.0 3.0 Expected dividend yield – –
Schedule of RSU activity	Schedule of RSU activity Number of RSUs Weighted Average Grant Date Fair Value RSUs outstanding at July 31, 2021 4,396,819 $ 1.09 RSUs issued 1,500,000 0.45 RSUs vested (3,707,124 ) 0.37 RSUs outstanding at July 31, 2022 2,189,695 0.23
Schedule of warrant activity	Schedule of warrant activity Number of Warrants Weighted Average Exercise Price Warrants outstanding at July 31, 2021 4,739,834 $ 1.05 Warrants issued 4,304,607 0.57 Warrants canceled (1,485,834 ) (1.50 ) Warrants outstanding at July 31, 2022 7,558,607 0.69

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Jul. 31, 2022
Equity [Abstract]
Schedule of Shares purchased	Schedule of Shares purchased Purchase Date Number of Shares Average Purchase Price per Share Total Purchase Price Remaining Purchase August 14, 2020 602,422 $ 0.410 $ 250,000 $ 10,000,000 January 2021 200,000 0.175 35,080 9,964,920 February 2021 330,106 0.626 206,798 9,758,122 March 2021 1,020,798 0.960 979,597 8,778,525 August 2021 600,000 0.397 237,940 8,540,585 September 2021 374,482 0.345 129,096 8,411,489 February 2022 100,000 0.515 51,500 8,359,989 March 2022 100,000 0.487 48,700 8,311,289 July 2022 421,119 0.194 81,556 8,229,733 3,748,927 0.539 $ 2,020,267

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	Schedule of Effective Income Tax Rate Reconciliation For the year ended July 31, 2022 2021 US federal statutory rates 21% 21% Valuation allowance (21 )% (21)% Effective tax rate 0% 0%
Schedule of Components of Income Tax Expense (Benefit)	Schedule of Components of Income Tax Expense (Benefit) For the year ended July 31, 2022 2021 Current deferred $ 885,400 $ 1,182,300 Increase in valuation allowance (885,400 ) (1,182,300 ) Total $ – $ –
Schedule of Deferred Tax Assets and Liabilities	Schedule of Deferred Tax Assets and Liabilities For the year ended July 31, 2022 2021 Deferred tax asset $ 2,475,100 $ 1,589,700 Valuation allowance (2,475,100 ) (1,589,700 ) Net deferred tax asset $ – $ –

Related Party Transactions (Tab

Related Party Transactions (Tables)	12 Months Ended
	Jul. 31, 2022
Related Party Transactions [Abstract]
Schedule of related party payables	Schedule of related party payables July 31, 2022 2021 Joseph M. Redmond, CEO $ 2,642 $ 2,568 Christine Farrell, CFO 745 – $ 3,387 $ 2,568
Schedule of accrued wages	Schedule of accrued wages July 31, 2022 2021 Joseph M. Redmond, CEO $ 696,154 $ 183,846 Christine Farrell, CFO 124,617 – $ 820,771 $ 183,846

Nature of Operations and Goin_2

Nature of Operations and Going Concern (Details Narrative) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 54,177,954	$ 45,733,823
Cash and cash equivalents	$ 72,534

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Accounting Policies [Abstract]
Fiscal 2023	$ 3,015
Fiscal 2024	3,015
Fiscal 2025	3,015
Fiscal 2026	3,015
Fiscal 2027	3,015
Thereafter	28,185
Total	$ 43,260	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details - Antidilutive shares) - shares	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	23,696,635	8,852,015
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	6,645,000	300,000
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	7,303,333	1,134,000
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	7,558,607	4,739,834
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	2,189,695	2,678,181

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Accounting Policies [Abstract]
Depreciation	$ 414	$ 552
Amortization expense	1,960	5,000
In-process research and development	$ 0	$ 9,440,000

Asset Purchase Agreement and _2

Asset Purchase Agreement and Asset Purchase Liability (Details Narrative) - Asset Purchase Agreement [Member] - Prevacus [Member]	7 Months Ended
	Mar. 01, 2021 USD ($) shares
Offsetting Assets [Line Items]
Stock issued for assets, shares | shares	7,000,000
Stock issued for assets, value	$ 7,080,000
Stock withheld for payment of liabilities, shares | shares	1,000,000
Stock withheld for payment of liabilities, value	$ 1,180,000
Stock issued for probable Milestone consideration, shares | shares	1,000,000
Stock issued for probable Milestone consideration, value	$ 1,180,000
Research and development	$ 9,440,000

Fair Value (Details)

Fair Value (Details) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Fair Value Disclosures [Abstract]
Carrying value	$ 1,580,000	$ 1,087,270
Fair value	$ 1,580,000	$ 1,094,212

Debt (Details)

Debt (Details) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Debt Instrument [Line Items]
Notes Payable	$ 1,580,000	$ 1,087,270
Unamortized debt discount and closing costs	(48,063)	(351,030)
Notes Payable current	1,531,937	736,240
Notes [Member] | Labrys [Member]
Debt Instrument [Line Items]
Notes Payable	0	37,270
Notes [Member] | Tysadco [Member]
Debt Instrument [Line Items]
Notes Payable	275,000	0
Convertible Notes [Member] | L G H [Member]
Debt Instrument [Line Items]
Notes Payable	1,180,000	1,050,000
Promissory Notes [Member]
Debt Instrument [Line Items]
Notes Payable	$ 125,000	$ 0

Debt (Details Narrative)

Debt (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

7 Months Ended

8 Months Ended

9 Months Ended

12 Months Ended

Mar. 03, 2022

Feb. 02, 2022

Jan. 05, 2022

Oct. 22, 2021

Aug. 14, 2020

Jun. 30, 2022

Mar. 31, 2022

Feb. 15, 2022

Aug. 29, 2021

May 31, 2021

Apr. 05, 2021

Mar. 31, 2022

Feb. 28, 2021

Apr. 05, 2021

Apr. 30, 2022

Apr. 30, 2021

Jul. 31, 2022

Jul. 31, 2021

Jun. 30, 2021

Debt Instrument [Line Items]

Debt face amount

$ 70,000

Stock issued new, shares

1,187,572

14,285,714

Stock issued new, value

$ 2,469,222

$ 2,980,975

Conversion price per share

$ 0.20

Consideration amount

$ 1,580,000

1,087,270

Interest expense

125,989

Balance debt

$ 1,180,000

Number of shares converted

6,320,000

Proceeds from notes payable

$ 375,000

1,565,000

Other income, net

$ 500,000

Conv Prom Note [Member]

Debt Instrument [Line Items]

Debt converted, shares issued

214,000

Debt converted, amount converted

$ 100,000

Debt converted, interest converted

7,000

Conv Prom Note 5 [Member]

Debt Instrument [Line Items]

Debt converted, shares issued

298,165

Debt converted, amount converted

$ 230,000

Debt converted, interest converted

$ 16,100

Conv Prom Note 4 [Member]

Debt Instrument [Line Items]

Debt converted, shares issued

127,063

Debt converted, amount converted

$ 95,000

Debt converted, interest converted

$ 6,650

Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Repayment of convertible debt

$ 20,000

Interest paid

$ 1,400

Ppp Loan [Member]

Debt Instrument [Line Items]

Other income, net

$ 50,000

Tysadco Partners [Member]

Debt Instrument [Line Items]

Warrant issued

1

Tysadco Partners [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Maturity date

Mar. 01, 2023

Mar. 01, 2022

Debt face amount

$ 250,000

Debt interest rate

8%

Proceeds from issuance of debt

$ 250,000

Stock issued new, shares

200,000

Stock issued new, value

$ 17,718

Conversion price per share

$ 0.30

Debt converted, shares issued

983,333

Consideration amount

$ 25,000

$ 25,000

LGH Amendment [Member] | Convertible Promissory Note [Member]

Debt Instrument [Line Items]

Maturity date

Aug. 30, 2022

Feb. 01, 2022

Conversion price per share

$ 0.20

Beneficial conversion feature

$ 200,100

LGH Amendment [Member] | Convertible Promissory Note [Member] | Minimum [Member]

Debt Instrument [Line Items]

Maturity date

Feb. 05, 2022

LGH Amendment [Member] | Convertible Promissory Note [Member] | Maximum [Member]

Debt Instrument [Line Items]

Maturity date

May 31, 2022

LGH Amendment [Member] | Convertible Promissory Note [Member] | Securities Purchase Agreement [Member]

Debt Instrument [Line Items]

Debt face amount

$ 1,050,000

$ 1,050,000

Debt interest rate

8%

8%

Stock issued new, shares

100,000

Stock issued new, value

$ 51,000

Conversion price per share

$ 1

$ 1

Debt converted, shares issued

1,336,000

Consideration amount

$ 200,000

$ 200,000

Proceeds from other debt

$ 250,000

L G H [Member]

Debt Instrument [Line Items]

Stock issued new, shares

100,000

Stock issued new, value

$ 51,000

L G H [Member] | April 2021 Prom Note [Member] | Lgh Agreement 2021 [Member]

Debt Instrument [Line Items]

Stock issued new, shares

100,000

Stock issued new, value

$ 85,000

Warrant issued

1,134,000

1,134,000

Warrant issued fair value

$ 877,716

$ 877,716

Total value of equity issued

463,968

L G H [Member] | April 2021 Prom Note [Member] | Lgh Agreement 2021 [Member] | Debt Discount [Member]

Debt Instrument [Line Items]

Warrant issued fair value

$ 423,003

423,003

L G H [Member] | April 2021 Prom Note [Member] | Lgh Agreement 2021 [Member] | Fair Value Of Common Stock [Member]

Debt Instrument [Line Items]

Stock issued new, value

$ 40,965

Labrys [Member] | Labrys Note [Member] | Labrys Spa [Member]

Debt Instrument [Line Items]

Debt face amount

$ 350,000

Stock issued new, shares

420,000

Stock issued new, value

$ 197,400

Proceeds from notes payable

315,000

Payment of stock issuance costs

25,200

Payment of other stock issuance costs

6,500

Total debt issuance costs

$ 31,700

The Notes [Member]

Debt Instrument [Line Items]

Proceeds from Debt

$ 125,000

Interest rate

8%

Maturity date

Dec. 31, 2022

The Notes [Member] | Redmond [Member]

Debt Instrument [Line Items]

Loans payable

$ 25,000

The Notes [Member] | Farrell [Member]

Debt Instrument [Line Items]

Loans payable

25,000

The Notes [Member] | Casey [Member]

Debt Instrument [Line Items]

Loans payable

25,000

The Notes [Member] | Gandolfo [Member]

Debt Instrument [Line Items]

Loans payable

25,000

The Notes [Member] | Richardson [Member]

Debt Instrument [Line Items]

Loans payable

25,000

Loans payable

$ 6,063

Stock-Based Awards (Details - S

Stock-Based Awards (Details - Stock Option Activity)	12 Months Ended
	Jul. 31, 2022 $ / shares shares
Equity [Abstract]
Options outstanding at begining balance | shares	1,050,000
Weighted Average Exercise Price at beginning balance | $ / shares	$ 1.22
Options issued | shares	5,595,000
Options issued | $ / shares	$ 0.32
Options outstanding at ending balance | shares	6,645,000
Weighted Average Exercise Price at ending balance | $ / shares	$ 0.46

Stock-Based Awards (Details - A

Stock-Based Awards (Details - Assumptions) - Equity Option [Member]	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility		155%
Risk free interest rate		0.08%
Expected life of options (years)		3 years
Expected dividend yield	0%	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility	137%
Risk free interest rate	1.17%
Expected life of options (years)	3 years
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility	149%
Risk free interest rate	3.02%
Expected life of options (years)	10 years

Stock-Based Awards (Details - R

Stock-Based Awards (Details - RSU Activity) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Jul. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Beginning balance | shares	4,396,819
Weighted Average Beginning balance | $ / shares	$ 1.09
RSUs issued | shares	1,500,000
Weighted Average Grant Date Fair Value Issued, issued | $ / shares	$ 0.45
RSUs vested | shares	(3,707,124)
Weighted Average Grant Date Fair Value Vested, vested | $ / shares	$ 0.37
Number of Shares Ending balance | shares	2,189,695
Weighted Average Ending balance | $ / shares	$ 0.23

Stock-Based Awards (Details - W

Stock-Based Awards (Details - Warrant Activity) - Warrant [Member]	12 Months Ended
	Jul. 31, 2022 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of Shares Beginning balance | shares	4,739,834
Weighted Average Beginning balance | $ / shares	$ 1.05
Warrants issued | shares	4,304,607
Weighted average exercise price, warrants issued | $ / shares	$ 0.57
Warrants canceled | shares	(1,485,834)
Weighted average exercise price, warrants canceled | $ / shares	$ (1.50)
Number of Shares Ending balance | shares	7,558,607
Weighted Average Ending balance | $ / shares	$ 0.69

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - USD ($)			12 Months Ended
	May 19, 2022	Sep. 14, 2021	Jul. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unrecognized stock-based compensation			$ 1,790,049
Weighted average remaining vesting period			1 year 5 months 4 days
Grants To Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Payment Arrangement, Noncash Expense			$ 155,033
Messrs Casey Conroy And Gandolfo [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures		500,000
Messrs Casey Conroy Gandolfo And Richardson [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures	500,000
Redmond [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures	750,000
Farrell [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures	600,000
Omnibus Stock Incentive Plan 2021 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares available for grant			13,355,000
Number of shares reserved			20,000,000

Common Stock (Details)

Common Stock (Details) - USD ($)				6 Months Ended	7 Months Ended	8 Months Ended	13 Months Ended	14 Months Ended	19 Months Ended	20 Months Ended	24 Months Ended
	Mar. 03, 2022	Feb. 02, 2022	Aug. 14, 2020	Jan. 31, 2021	Feb. 28, 2021	Mar. 31, 2021	Aug. 31, 2021	Sep. 30, 2021	Feb. 28, 2022	Mar. 31, 2022	Jul. 31, 2022	Jul. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued new, shares	1,187,572	14,285,714
Lincoln Park Capital Fund [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock issued new, shares			602,422	200,000	330,106	1,020,798	600,000	374,482	100,000	100,000	421,119	3,748,927
Stock price per share			$ 0.410	$ 0.175	$ 0.626	$ 0.960	$ 0.397	$ 0.345	$ 0.515	$ 0.487	$ 0.194	$ 0.539
Proceeds from sale of stock			$ 250,000	$ 35,080	$ 206,798	$ 979,597	$ 237,940	$ 129,096	$ 51,500	$ 48,700	$ 81,556	$ 2,020,267
Remaining Purchase Availability			$ 10,000,000	$ 9,964,920	$ 9,758,122	$ 8,778,525	$ 8,540,585	$ 8,411,489	$ 8,359,989	$ 8,311,289	$ 8,229,733

Common Stock (Details Narrative

Common Stock (Details Narrative) - USD ($)

1 Months Ended

3 Months Ended

5 Months Ended

6 Months Ended

7 Months Ended

8 Months Ended

11 Months Ended

12 Months Ended

13 Months Ended

14 Months Ended

19 Months Ended

20 Months Ended

24 Months Ended

Jun. 10, 2022

May 08, 2022

Apr. 14, 2022

Mar. 03, 2022

Feb. 09, 2022

Feb. 02, 2022

Oct. 22, 2021

Oct. 18, 2021

Mar. 01, 2021

Feb. 12, 2021

Aug. 14, 2020

Jul. 27, 2022

Jul. 20, 2022

May 19, 2022

Oct. 22, 2021

Oct. 18, 2021

Jul. 31, 2021

Jun. 30, 2021

Jan. 31, 2021

Mar. 31, 2022

Dec. 29, 2021

Dec. 21, 2021

Jan. 31, 2021

Feb. 28, 2021

Mar. 31, 2021

Jun. 30, 2021

Jul. 31, 2022

Jul. 31, 2021

Aug. 31, 2021

Sep. 30, 2021

Feb. 28, 2022

Mar. 31, 2022

Jul. 31, 2022

Jul. 31, 2022

Class of Stock [Line Items]

General and administrative expenses

$ 6,789,556

$ 4,788,119

Number of share issued

1,187,572

14,285,714

Number of shares granted

5,595,000

Warrants exercise price

$ 0.35

Other accrued payables

$ 13,750

$ 13,750

$ 13,750

Issuance of shares value

$ 2,469,222

2,980,975

Sale of stock per share

$ 0.35

Minimum amount

$ 1,000,000

Units issued

2,870,800

2,870,800

2,870,800

Gross proceeds

$ 415,650

Net proceeds

$ 849,302

Commissions and fees

$ 374,085

Warrant issued

608,755

Cash

$ 556,584

$ 72,534

$ 556,584

$ 72,534

$ 72,534

Common Stock [Member]

Class of Stock [Line Items]

Number of share issued

1,187,572

8,653,973

4,932,962

Share price

$ 0.25

Issuance of shares value

$ 8,655

$ 4,933

Warrants purchased

593,786

Per Amended Employment Agreement [Member]

Class of Stock [Line Items]

Stock compensation expense

$ 53,000

Stock issued for compensation, shares

5,300,000

Investor [Member]

Class of Stock [Line Items]

General and administrative expenses

$ 16,650

$ 40,000

$ 115,000

Number of shares granted

45,000

200,000

500,000

Units issued

1,435,400

1,435,400

1,435,400

Gross proceeds

$ 1,004,780

Prevacus [Member]

Class of Stock [Line Items]

Number of share issued

1,000,000

Restricted Stock [Member]

Class of Stock [Line Items]

Number of share issued

3,000,000

Share price

$ 0.53

Investor Warrants [Member]

Class of Stock [Line Items]

Warrants exercise price

$ 0.70

Warrants term

5 years

Vivakor Inc [Member]

Class of Stock [Line Items]

Treasury stock, shares

3,309,578

Regal Growth LLC [Member]

Class of Stock [Line Items]

Treasury stock, shares

5,000,000

LBL Professional Consulting, Inc [Member]

Class of Stock [Line Items]

Treasury stock, shares

7,500,000

P L C Investments Inc [Member]

Class of Stock [Line Items]

Treasury stock, shares

7,370,000

Green Energy Alternatives [Member]

Class of Stock [Line Items]

Treasury stock, shares

5,300,000

Electromedica [Member]

Class of Stock [Line Items]

Treasury stock, shares

15,000,000

Consultant [Member] | Consulting Services Agreements [Member]

Class of Stock [Line Items]

Stock granted to related party

25,000

75,000

540,000

General and administrative expenses

$ 29,500

$ 93,750

$ 88,000

Mr Redmond [Member]

Class of Stock [Line Items]

Shares received

5,300,000

5,300,000

Tysadco Partners [Member]

Class of Stock [Line Items]

Share price

$ 0.59

$ 0.59

Number of stock sold

500,000

Warrants exercisable

500,000

Warrants issued, common shares eligible

1

1

Tysadco Partners [Member] | Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Proceeds from sale of stock

$ 250,000

Tysadco Partners [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]

Class of Stock [Line Items]

Number of share issued

1,500,000

Tysadco Partners [Member] | Securities Purchase Agreement [Member] | Warrants [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

833,333

Warrants exercise price

$ 0.50

$ 0.50

Warrants term

5 years

5 years

Tysadco Partners [Member] | Consulting Services Agreements [Member]

Class of Stock [Line Items]

Proceeds from sale of stock

$ 250,000

Purchase Price

295,000

Due to related parties

$ 45,000

$ 45,000

Lincoln Park Capital Fund [Member]

Class of Stock [Line Items]

Number of share issued

602,422

200,000

330,106

1,020,798

600,000

374,482

100,000

100,000

421,119

3,748,927

Proceeds from sale of stock

$ 250,000

$ 35,080

$ 206,798

$ 979,597

$ 237,940

$ 129,096

$ 51,500

$ 48,700

$ 81,556

$ 2,020,267

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member]

Class of Stock [Line Items]

Proceeds from sale of stock

$ 250,000

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member] | Restricted Common Stock [Member]

Class of Stock [Line Items]

Number of share issued

1,500,000

Lincoln Park Capital Fund [Member] | Securities Purchase Agreement [Member] | Warrants [Member]

Class of Stock [Line Items]

Stock Issued During Period, Shares, New Issues

833,333

Warrants exercise price

$ 0.50

$ 0.50

Warrants term

5 years

5 years

Lincoln Park Capital Fund [Member] | Purchase Agreement [Member]

Class of Stock [Line Items]

Number of share issued

793,802

Proceeds from sale of stock

$ 250,000

Lincoln Park Capital Fund [Member] | Initial Purchase [Member]

Class of Stock [Line Items]

Number of share issued

602,422

A G P [Member]

Class of Stock [Line Items]

Warrants exercise price

$ 0.50

Warrants issued, common shares eligible

550,000

Payment of placement agent fees

$ 20,000

Payment for fees

$ 97,718

Warrants issued, value

$ 220,000

Warrants expiration date

Aug. 06, 2024

L G H [Member]

Class of Stock [Line Items]

Number of share issued

100,000

Issuance of shares value

$ 51,000

Laidlaw [Member]

Class of Stock [Line Items]

Cash

$ 100,478

$ 100,478

$ 100,478

Income Taxes (Details - Income

Income Taxes (Details - Income Tax Rate Reconciliation)	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Income Tax Disclosure [Abstract]
US federal statutory rates	21%	21%
Valuation allowance	(21.00%)	(21.00%)
Effective tax rate	0%	0%

Income Taxes (Details - Tax pro

Income Taxes (Details - Tax provision (benefit)) - USD ($)	12 Months Ended
	Jul. 31, 2022	Jul. 31, 2021
Income Tax Disclosure [Abstract]
Current deferred	$ 885,400	$ 1,182,300
Increase in valuation allowance	(885,400)	(1,182,300)
Total	$ 0	$ 0

Income Taxes (Details - Deferre

Income Taxes (Details - Deferred tax asset) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Income Tax Disclosure [Abstract]
Deferred tax asset	$ 2,475,100	$ 1,589,700
Valuation allowance	(2,475,100)	(1,589,700)
Net deferred tax asset	$ 0	$ 0

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Jul. 31, 2022 USD ($)
Income Tax Disclosure [Abstract]
Net operating loss carryforwards expiration date	2036
Net operating loss carryforwards	$ 11,434,941
Unrecognized Tax Benefits	$ 0

Related Party Transactions (Det

Related Party Transactions (Details - Due to officers) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	$ 3,387	$ 2,568
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	2,642	2,568
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Due to related party	$ 745	$ 0

Related Party Transactions (D_2

Related Party Transactions (Details - Accrued Compensation) - USD ($)	Jul. 31, 2022	Jul. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	$ 820,771	$ 183,846
Chief Executive Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	696,154	183,846
Chief Financial Officer [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Salary and bonus payable	$ 124,617	$ 0

Related Party Transactions (D_3

Related Party Transactions (Details Narrative) - USD ($)	7 Months Ended	12 Months Ended
	Mar. 01, 2021	Jul. 31, 2022	Jul. 31, 2021
Related Party Transaction [Line Items]
Notes payable		$ 1,580,000	$ 1,087,270
General and administrative expenses		6,789,556	4,788,119
Other expenses		49,010
Mr Redmond [Member]
Related Party Transaction [Line Items]
Bonus paid		360,000
Ms Farrell [Member]
Related Party Transaction [Line Items]
Bonus paid		40,000
Officers and Directors [Member]
Related Party Transaction [Line Items]
Notes payable		25,000
Vanlandingham [Member]
Related Party Transaction [Line Items]
Options granted	$ 1,000,000
Fair value of options granted	$ 941,000
General and administrative expenses		295,845	$ 596,145
Due from Related Parties		$ 27,500

Donation Received (Details Narr

Donation Received (Details Narrative)	Jan. 05, 2022 USD ($)
Donation Received
Other income	$ 500,000

Research and Development Reba_2

Research and Development Rebate (Details Narrative)	12 Months Ended
	Jul. 31, 2022 USD ($)
Research and Development [Abstract]
Research and development	$ 264,209
Prepaid expenses and other current assets	$ 366,475